Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oxaliplatin: practical guidelines for administration.

Joan Sorich1, Beth Taubes, Allan Wagner

  • 1j_sorich@hotmail.com

Clinical Journal of Oncology Nursing
|June 24, 2004
PubMed
Summary

Colorectal cancer (CRC) treatment is improving with oxaliplatin, a key chemotherapy drug. Proper administration and patient education are crucial for maximizing its effectiveness and safety in managing this disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3.

The oncologist·2026
Same author

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

Journal of the National Cancer Institute·2026
Same author

Diversity, equity, and inclusion as scientific rigor: progress during challenging times.

JNCI cancer spectrum·2026
Same author

Phase II Study of Pegvorhyaluronidase Alfa (PEGPH20) and Pembrolizumab for Patients with Hyaluronan-High, Pretreated Metastatic Pancreatic Ductal Adenocarcinoma: PCRT16-001.

Cancers·2026
Same author

NCI9673 (Part B): ETCTN Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Refractory, Metastatic Squamous Cell Carcinoma of the Anal Canal.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Endoscopic liquid biopsies of gastric fluid in a large human patient cohort reveal DNA content as a candidate tumor biomarker in gastric cancer.

eLife·2025

Area of Science:

  • Oncology
  • Medical Chemistry

Background:

  • Colorectal cancer (CRC) represents a significant public health concern, accounting for 11% of new cancer cases in the US and causing substantial mortality.
  • Current antineoplastic agents offer palliation and improved quality of life but highlight the need for enhanced therapeutic options.

Purpose of the Study:

  • To review the administration guidelines, adverse events, and side effects of oxaliplatin, a chemotherapy agent for colorectal cancer.
  • To identify key areas for patient education to optimize oxaliplatin therapy.

Main Methods:

  • Literature review of oxaliplatin administration, efficacy, and safety data.
  • Analysis of reported adverse events and side effects associated with oxaliplatin treatment.
  • Identification of essential patient education components for CRC patients receiving oxaliplatin.

Main Results:

  • Oxaliplatin, approved in August 2002, provides an effective treatment option for colorectal cancer.
  • Proper dosage and administration are critical for maximizing oxaliplatin's therapeutic benefits and minimizing risks.
  • Understanding and managing adverse events and side effects are essential for patient care.

Conclusions:

  • Oxaliplatin is a valuable addition to the colorectal cancer treatment armamentarium.
  • Emphasis on correct administration protocols and comprehensive patient education is vital for successful outcomes.
  • Ongoing research and clinical practice should focus on optimizing oxaliplatin's role in CRC management.

Related Experiment Videos